Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies

BACKGROUND: Conventional oral corticosteroids are effective at reducing inflammation associated with ulcerative colitis (UC); however, systemic adverse effects limit their use. Budesonide MMX is an extended‐release, second‐generation corticosteroid that targets delivery of budesonide to the entire c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandborn, W. J., Danese, S., D'Haens, G., Moro, L., Jones, R., Bagin, R., Huang, M., David Ballard, E., Masure, J., Travis, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681012/
https://www.ncbi.nlm.nih.gov/pubmed/25588902
http://dx.doi.org/10.1111/apt.13076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681012/
https://www.ncbi.nlm.nih.gov/pubmed/25588902
http://dx.doi.org/10.1111/apt.13076

Ejemplares similares